Physician profile
Janet Ihde
NPI 1063488872
$1,626.63
in general payments reported to CMS, 2019-2025
34 companies · $599 in 2025
The $599 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $20.79 · 2021: $22.17 · 2022: $144 · 2023: $237 · 2024: $311 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $174.12 | 2024-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $157.31 | 2022-2023 | Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $121.05 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $111.03 | 2019 | |
| Mentor Worldwide LLC | $84.76 | 2019 | |
| Merck Sharp & Dohme LLC | $73.81 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pfizer INC. | $62.49 | 2024 | |
| Abbvie INC. | $58.61 | 2025 | |
| Janssen Biotech, INC. | $50.64 | 2023-2025 | Darzalex, Talvey, Imbruvica |
| Ge Healthcare | $48.38 | 2025 | |
| Springworks Therapeutics, INC. | $47.73 | 2025 | Ogsiveo |
| Gilead Sciences, INC. | $42.73 | 2023-2024 | |
| Amgen INC. | $40.52 | 2022 | |
| Deciphera Pharmaceuticals INC. | $40.50 | 2024-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $39.79 | 2025 | Tevimbra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $37.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.62 | 2024 | |
| Intuitive Surgical, INC. | $34.56 | 2024 | |
| Genzyme Corporation | $34.11 | 2022 | |
| Karyopharm Therapeutics INC. | $31.02 | 2025 | Xpovio |
| Astellas Pharma US INC | $30.73 | 2024 | Padcev |
| Glaxosmithkline, LLC. | $30.30 | 2025 | Jemperli, Zejula |
| Incyte Corporation | $25.87 | 2022-2023 | Jakafi |
| Celgene Corporation | $25.00 | 2019 | |
| Sobi, INC | $24.03 | 2024 | |
| Eisai INC. | $22.17 | 2021 | |
| Hologic Sales and Service, LLC | $20.96 | 2024 | Brevera Breast Biopsy System, 3dquorum |
| Seagen INC. | $19.96 | 2022 | |
| Emd Serono, INC. | $19.12 | 2024 | |
| Lilly USA, LLC | $17.99 | 2024 | Verzenio, Jaypirca |
| Pharmaessentia USA Corporation | $17.01 | 2025 | Besremi |
| Foundation Medicine, INC. | $15.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.72 | 2023 | |
| Daiichi Sankyo INC. | $14.49 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Ihde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.